BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 16024608)

  • 1. The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha.
    Puccetti E; Zheng X; Brambilla D; Seshire A; Beissert T; Boehrer S; Nürnberger H; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
    Cancer Res; 2005 Jul; 65(14):6080-8. PubMed ID: 16024608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-function studies of the BTB/POZ transcriptional repression domain from the promyelocytic leukemia zinc finger oncoprotein.
    Li X; Peng H; Schultz DC; Lopez-Guisa JM; Rauscher FJ; Marmorstein R
    Cancer Res; 1999 Oct; 59(20):5275-82. PubMed ID: 10537309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides.
    Beez S; Demmer P; Puccetti E
    PLoS One; 2012; 7(11):e48636. PubMed ID: 23152790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formation of PML/RAR alpha high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RAR alpha-mediated retinoic acid response.
    Grignani F; Gelmetti V; Fanelli M; Rogaia D; De Matteis S; Ferrara FF; Bonci D; Grignani F; Nervi C; Pelicci PG
    Oncogene; 1999 Nov; 18(46):6313-21. PubMed ID: 10597230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
    Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
    Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex.
    Puccetti E; Sennewald B; Fosca-Ferrara F; Boehrer S; Bianchini A; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
    Hematol J; 2001; 2(6):385-92. PubMed ID: 11920278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors.
    Melnick A; Carlile G; Ahmad KF; Kiang CL; Corcoran C; Bardwell V; Prive GG; Licht JD
    Mol Cell Biol; 2002 Mar; 22(6):1804-18. PubMed ID: 11865059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions.
    Melnick A; Ahmad KF; Arai S; Polinger A; Ball H; Borden KL; Carlile GW; Prive GG; Licht JD
    Mol Cell Biol; 2000 Sep; 20(17):6550-67. PubMed ID: 10938130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Essential role for the dimerization domain of NuMA-RARalpha in its oncogenic activities and localization to NuMA sites within the nucleus.
    Dong S; Qiu J; Stenoien DL; Brinkley WR; Mancini MA; Tweardy DJ
    Oncogene; 2003 Feb; 22(6):858-68. PubMed ID: 12584566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
    Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
    Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein.
    Oncogene; ; . PubMed ID: 9627120
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.